Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc?RIIb. Zenas BioPharma Inc. is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | $10.00M |
| Net Income (Most Recent Fiscal Year) | $-377.74M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.97 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3778.16% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -99.99% |
| Return on Assets (Trailing 12 Months) | -58.06% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.94 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.94 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.04 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $4.51 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.46 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-8.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 63.13M |
| Free Float | 49.24M |
| Market Capitalization | $1.10B |
| Average Volume (Last 20 Days) | 0.51M |
| Beta (Past 60 Months) | -0.71 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 22.00% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |